Other biomarkers such as Carcinoembryonic Antigen (CEA) or cell surface associated mucin 1 (MUC-1) have also shown promise in detecting pancreatic cancer by sampling the circulation, but they have suffered from the same lack of specificity and sensitivity that prevent them from being routinely recommended for patients [3,4]. The gene discussed is CEACAM5; the disease is familial pancreatic carcinoma.